REPRO-MED Systems (KRMD) AI Stock Analysis

• Market Cap: $178.47M
• Dividend Yield: N/A
• Average Volume (3M): 91.82K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.83
• Revenue Growth: 22.12%
• EPS Growth: 69.19%
• Country: US
• Employees: 80
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.02
• Shares Outstanding: 46,234,960
• 10 Day Avg. Volume: 54,917
• 30 Day Avg. Volume: 91,822
• PEG Ratio: 0.51
• Price to Book (P/B): 10.49
• Price to Sales (P/S): 5.24
• P/FCF Ratio: -109.04
• Enterprise Value/Market Cap: 0.90
• Enterprise Value/Revenue: 4.12
• Enterprise Value/Gross Profit: 6.60
• Enterprise Value/Ebitda: -50.28
• 1Y Price Target: $5.00
• Price Target Upside: 20.77% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 59 Neutral
• Price Target: $5.50 ▲(32.85% Upside)

The overall stock score is primarily influenced by strong technical momentum and positive earnings call highlights, including international expansion and strategic advancements. However, financial performance struggles and poor valuation metrics weigh down the score.

Positive Factors

International Market Expansion

The substantial growth in international markets, particularly in Europe, indicates a successful expansion strategy that could provide a durable revenue stream and reduce dependency on domestic markets.

Core Business Performance

The strong growth in the SCIG business highlights the company's competitive advantage in a niche market, supporting long-term revenue growth and market leadership in infusion therapy.

Increased Revenue Guidance

The increased revenue guidance reflects management's confidence in sustained growth, driven by strategic initiatives and market demand, which is crucial for long-term financial health.

Negative Factors

Gross Margin Challenge

The decline in gross margin indicates potential challenges in cost management, which could pressure profitability and affect the company's ability to reinvest in growth.

Cash Flow Management

The sharp decline in free cash flow growth suggests difficulties in converting revenue into cash, which may limit the company's operational flexibility and investment capacity.

Pipeline Launch Delays

Delays in pipeline launches can hinder future revenue streams and slow down strategic growth initiatives, affecting long-term competitive positioning.

REPRO-MED Systems Business Overview & Revenue Model

Company Description

REPRO-MED Systems, Inc. (KRMD) is a medical technology company that specializes in the development and commercialization of innovative medical devices and services for patients with chronic conditions. The company primarily focuses on the areas of infusion therapy, specifically in the management of patients requiring subcutaneous drug delivery. Its core products include the DME (Durable Medical Equipment) infusion pump systems, which are designed to improve the quality of life for patients with complex medical needs.

How the Company Makes Money

REPRO-MED Systems generates revenue primarily through the sale of its infusion pump systems and related consumables. This includes the sale of its proprietary infusion devices, which are used for the administration of medication to patients. Additionally, the company earns revenue from the provision of service contracts for the maintenance of its devices. Key revenue streams include direct sales to healthcare providers, hospitals, and home healthcare agencies. The company also benefits from partnerships with pharmaceutical companies for the development of customized solutions for drug delivery, which can lead to additional revenue opportunities. Furthermore, REPRO-MED Systems may receive reimbursements from insurance providers for the sale of its products, contributing to its overall earnings.

REPRO-MED Systems Financial Statement Overview

Summary

REPRO-MED Systems shows revenue growth but struggles with profitability and cash flow management. The balance sheet is stable with moderate leverage, but negative returns on equity and cash flow challenges highlight areas for improvement.

Income Statement

REPRO-MED Systems shows a positive revenue growth rate of 6.03% TTM, indicating some growth potential. However, the company struggles with profitability, as evidenced by negative net profit, EBIT, and EBITDA margins. The gross profit margin is relatively strong at 62.32% TTM, but the consistent negative net profit margin highlights ongoing challenges in managing costs and achieving profitability.

Balance Sheet

The company maintains a moderate debt-to-equity ratio of 0.20 TTM, suggesting a conservative approach to leverage. However, the return on equity is negative, reflecting ongoing losses. The equity ratio is not explicitly calculated, but the relatively low debt levels indicate a stable financial structure, albeit with profitability concerns.

Cash Flow

REPRO-MED Systems faces challenges in cash flow management, with a significant decline in free cash flow growth of -91.93% TTM. The operating cash flow to net income ratio is low at 0.04, indicating limited cash generation from operations relative to net income. The negative free cash flow to net income ratio further underscores cash flow difficulties.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	39.07M	33.65M	28.52M	27.90M	23.49M	24.18M
Gross Profit	24.35M	21.33M	16.71M	15.37M	13.77M	14.94M
EBITDA	-3.20M	-5.67M	-9.40M	-10.19M	-6.57M	1.61M
Net Income	-3.71M	-6.07M	-13.74M	-8.66M	-4.56M	-1.21M
Balance Sheet
Total Assets	27.10M	27.22M	28.46M	42.33M	41.29M	39.92M
Cash, Cash Equivalents and Short-Term Investments	8.46M	9.58M	11.48M	17.41M	25.33M	27.32M
Total Debt	3.67M	3.99M	4.45M	4.93M	604.14K	239.49K
Total Liabilities	10.64M	10.40M	8.11M	11.01M	4.79M	3.76M
Stockholders Equity	16.46M	16.81M	20.35M	31.33M	36.50M	36.16M
Cash Flow
Free Cash Flow	-173.91K	-1.62M	-5.71M	-8.21M	-4.69M	-1.80M
Operating Cash Flow	307.26K	-319.72K	-4.89M	-5.40M	-4.32M	-743.32K
Investing Cash Flow	-477.40K	-1.33M	-814.60K	-2.80M	-366.17K	-1.04M
Financing Cash Flow	-172.16K	-248.53K	-218.87K	279.49K	2.71M	23.22M

REPRO-MED Systems Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.14
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KRMD, the sentiment is Positive. The current price of 4.14 is below the 20-day moving average (MA) of 4.49, below the 50-day MA of 4.22, and above the 200-day MA of 3.52, indicating a bullish trend. The MACD of 0.42 indicates Negative momentum. The RSI at 79.34 is Negative, neither overbought nor oversold. The STOCH value of 92.51 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KRMD.

REPRO-MED Systems Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INFU	63 Neutral	$182.42M	35.70	9.95%	―	6.23%	283.88%
UTMD	63 Neutral	$175.82M	15.53	9.59%	2.09%	-12.35%	-17.20%
KRMD	59 Neutral	$178.47M	-39.27	-21.71%	―	22.12%	69.19%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OSUR	48 Neutral	$179.33M	―	-15.30%	―	-43.95%	-620.21%

REPRO-MED Systems Corporate Events

REPRO-MED Systems Signs New Manufacturing Agreement

On November 19, 2025, REPRO-MED Systems entered into an Amended and Restated Manufacturing and Supply Agreement with Command Medical Products, Inc. This agreement, effective January 1, 2024, outlines the manufacturing and supply of subassemblies, needle sets, and tubing products, and will expire on December 31, 2026, with automatic renewals unless terminated by either party. It includes terms on pricing, payment, and purchase commitments, as well as provisions for delivery, inspection, warranties, and intellectual property.

The most recent analyst rating on (KRMD) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on REPRO-MED Systems stock, see the KRMD Stock Forecast page.

Repro-Med Systems’ Earnings Call Highlights Growth and Challenges

In the recent earnings call, Repro-Med Systems, Inc. demonstrated a generally positive sentiment, underscored by robust revenue growth, particularly from international markets, and strategic advancements in oncology. However, the company also faced challenges such as a decline in domestic revenue, gross margin pressures, and delays in their pipeline.

KORU Medical Systems Reports Strong Q3 Growth

KORU Medical Systems, Inc., a prominent player in the medical technology sector, specializes in developing, manufacturing, and commercializing large volume subcutaneous infusion solutions aimed at enhancing patient care globally.